Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference
April 28 2021 - 8:07PM
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of innovative, disease-modifying therapies for neurodegenerative
diseases, today announced that Richard Peters, M.D., Ph.D.,
President and Chief Executive Officer, will present at the 2021 B.
Riley Securities’ Neuroscience Conference.
The presentation will be available on-demand via the conference
portal and through the Company's website at www.yumanity.com/events
beginning at 2:30 p.m. EDT, April 29.
About Yumanity TherapeuticsYumanity
Therapeutics is a clinical-stage biopharmaceutical company
dedicated to accelerating the revolution in the treatment of
neurodegenerative diseases through its scientific foundation and
drug discovery platform. The Company’s most advanced product
candidate, YTX-7739, is currently in Phase 1 clinical development
for Parkinson’s disease. Yumanity’s drug discovery platform enables
the Company to rapidly screen for potential disease-modifying
therapies by overcoming the toxicity of misfolded proteins
associated with neurogenerative diseases. Yumanity’s pipeline
consists of additional programs focused on Lewy body dementia,
multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou
Gehrig’s disease), frontotemporal lobar dementia (FTLD), and
Alzheimer’s disease. For more information, please visit
www.yumanity.com.
Investors:Burns McClellan, Inc.Lee
Rothlroth@burnsmc.com(212) 213-0006
Media:Burns McClellan, Inc.Ryo Imai / Robert
Flamm, Ph.D.rimai@burnsmc.com / rflamm@burnsmc.com(212)
213-0006
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024